Published in TB and Outbreaks Week, August 20th, 2002
"Moxifloxacin (MXF) is a new 8-methoxyquinolone with potent activity against Mycobacterium tuberculosis and a half-life of 9 to 12 h in humans," explained Dr. Tetsuyuki Yoshimatsu and colleagues at Johns Hopkins University School of Medicine in Baltimore and Pitie Salpetriere School of Medicine in Paris. "Previous in vivo studies using daily doses of 100 mg/kg of body weight have demonstrated bactericidal activity comparable to that of isoniazid (INH) in a murine model of tuberculosis (TB)."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week